To design high affinity D-peptide antagonist of the oncoprotein MDM2 for potential anticancer therapy. Methods All peptides and proteins were chemically synthesized and were purified to homogeneity by reverse-phase HPLC. Quantification of the binding affinity of D-peptide for MDM2 was performed on a Biacore T100 instrument using SPR-based competitive binding method and a Tecan Infinite M1000 fluorescence plate reader using fluorescence polarization assay. Crystallization screening was conducted at room temperature using the hanging-drop vapor diffusion method and commercial crystallization matrices (Hampton). 
D
PMI-β for MDM2 by 80-fold, which is structurally rationalized by X-ray crystallography. A modest 2-fold improvement in binding affinity for MDM2 ensues upon the substitution of 6-F-Trp for Trp3. In combination, both changes additively enhance 
